Literature DB >> 15389788

Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment.

Nina Ohlson1, Pernilla Wikström, Pär Stattin, Anders Bergh.   

Abstract

BACKGROUND: Androgen ablation is the standard treatment for advanced prostate cancer but the short-term cellular effects are largely unknown.
METHODS: Sextant prostate biopsies were taken from 77 prostate cancer patients before and 1-10 days after castration treatment. Apoptosis, cell proliferation, and morphology were studied in malignant and non-malignant tissue, using stereological and immunohistochemical methods.
RESULTS: Epithelial cell proliferation was significantly decreased both in non-malignant and malignant epithelium already 1 day after therapy. It remained low until day 7, but increased thereafter in the remaining non-malignant epithelial cells and in some tumors. Epithelial cell apoptosis was significantly increased during the first week and then returned to basal levels. The maximal apoptotic indexes, seven- and two-times the intact levels in the non-malignant and malignant glands, respectively, were found at days 3-4 or even earlier in the tumors. Signs of tumor shrinkage such as glandular collapse and decreased tumor cell size were observed from day 3 in most tumors. DISCUSSION: The present study shows that the magnitude and kinetics of the response to castration in the normal human prostate is very similar to the response previously described in rodents. We also demonstrate that most human prostate tumors rapidly respond to castration indicating the need for further evaluation of when and how to best monitor the effects of hormone ablation therapy in prostate cancer patients. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389788     DOI: 10.1002/pros.20139

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

1.  Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells.

Authors:  Cecilia Colombero; Daniela Papademetrio; Paula Sacca; Eduardo Mormandi; Elida Alvarez; Susana Nowicki
Journal:  Horm Cancer       Date:  2017-06-21       Impact factor: 3.869

Review 2.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

3.  Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

Authors:  Akash K Kaushik; Shaiju K Vareed; Sumanta Basu; Vasanta Putluri; Nagireddy Putluri; Katrin Panzitt; Christine A Brennan; Arul M Chinnaiyan; Ismael A Vergara; Nicholas Erho; Nancy L Weigel; Nicholas Mitsiades; Ali Shojaie; Ganesh Palapattu; George Michailidis; Arun Sreekumar
Journal:  J Proteome Res       Date:  2013-12-31       Impact factor: 4.466

4.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Authors:  Vassiliki Tzelepi; Eleni Efstathiou; Sijin Wen; Patricia Troncoso; Maria Karlou; Curtis A Pettaway; Louis L Pisters; Anh Hoang; Christopher J Logothetis; Lance C Pagliaro
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

5.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.

Authors:  Jennifer S Davis; Kent L Nastiuk; John J Krolewski
Journal:  Mol Endocrinol       Date:  2011-02-03

Review 6.  Androgens, aging, and prostate health.

Authors:  Karin Welén; Jan-Erik Damber
Journal:  Rev Endocr Metab Disord       Date:  2022-06-24       Impact factor: 6.514

7.  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Authors:  Dana Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 8.  The basic biochemistry and molecular events of hormone therapy.

Authors:  Elahe A Mostaghel; Robert B Montgomery; Daniel W Lin
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

9.  High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.

Authors:  Andrew C Haller; Wei Tan; Rochelle Payne-Ondracek; Willie Underwood; Lili Tian; Carl Morrison; Fengzhi Li
Journal:  Prostate       Date:  2013-12-27       Impact factor: 4.104

10.  Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.

Authors:  Diego J Bedoya; Nicholas Mitsiades
Journal:  Onco Targets Ther       Date:  2013-01-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.